Durvalumab + S-488210/S-488211
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Mar 25, 2022 → May 31, 2029
NCT ID
NCT04106115About Durvalumab + S-488210/S-488211
Durvalumab + S-488210/S-488211 is a phase 1/2 stage product being developed by Shionogi for Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04106115. Target conditions include Bladder Cancer.
What happened to similar drugs?
10 of 20 similar drugs in Bladder Cancer were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04106115 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Bladder Cancer